TY - JOUR
AU - Grobbee D.
AU - Travert F.
AU - de Galan Bastiaan
AU - Lisheng L.
AU - Dufouil C.
AU - Woodward Mark
AU - Zoungas Sophia
AU - Pillai A.
AU - Poulter N.
AU - Anderson Craig
AU - Hamet P.
AU - Mancia G.
AU - Heller S.
AU - Cooper M.
AU - Pan C.
AU - J Chalmers
AU - Hackett M
AU - Neal Bruce
AU - Patel Anushka
AU - Macmahon S
AB - <p>
AIMS/HYPOTHESIS: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. METHODS: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n = 8,689), 24-27 ('mild dysfunction', n = 2,231) and &lt;24 ('severe dysfunction', n = 212). Risks of major cardiovascular events, death and hypoglycaemia and interactions with treatment were assessed using Cox proportional hazards analysis. RESULTS: Relative to normal function, both mild and severe cognitive dysfunction significantly increased the multiple-adjusted risks of major cardiovascular events (HR 1.27, 95% CI 1.11-1.46 and 1.42, 95% CI 1.01-1.99; both p &lt; 0.05), cardiovascular death (1.41, 95% CI 1.16-1.71 and 1.56, 95% CI 0.99-2.46; both p
</p>

AD - The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.
AN - 19688336
BT - Diabetologia
ET - 2009/08/19
LA - eng
M1 - 11
N1 - de Galan, B EZoungas, SChalmers, JAnderson, CDufouil, CPillai, ACooper, MGrobbee, D EHackett, MHamet, PHeller, S RLisheng, LMacmahon, SMancia, GNeal, BPan, C YPatel, APoulter, NTravert, FWoodward, MADVANCE Collaborative GroupResearch Support, Non-U.S. Gov'tGermanyDiabetologiaDiabetologia. 2009 Nov;52(11):2328-36. Epub 2009 Aug 18.
N2 - <p>
AIMS/HYPOTHESIS: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. METHODS: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n = 8,689), 24-27 ('mild dysfunction', n = 2,231) and &lt;24 ('severe dysfunction', n = 212). Risks of major cardiovascular events, death and hypoglycaemia and interactions with treatment were assessed using Cox proportional hazards analysis. RESULTS: Relative to normal function, both mild and severe cognitive dysfunction significantly increased the multiple-adjusted risks of major cardiovascular events (HR 1.27, 95% CI 1.11-1.46 and 1.42, 95% CI 1.01-1.99; both p &lt; 0.05), cardiovascular death (1.41, 95% CI 1.16-1.71 and 1.56, 95% CI 0.99-2.46; both p
</p>

PY - 2009
SN - 1432-0428 (Electronic)0012-186X (Linking)
SP - 2328
EP - 36
T2 - Diabetologia
TI - Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
VL - 52
ER -